TG Therapeutics, Inc.
NASDAQTG Therapeutics reported Q1 2026 results today with a notable split: revenue of $204.9 million beat the $196.8 million consensus estimate, while adjusted EPS of $0.18 missed the $0.30 estimate by a wide margin. The company raised full-year 2026 sales guidance to $925 million, ahead of the $906 million analyst estimate. That combination — a top-line beat paired with a bottom-line…
Snapshot as of 6 May 2026
TG Therapeutics reported Q1 2026 results today with a notable split: revenue of $204.9 million beat the $196.8 million consensus estimate, while adjusted EPS of $0.18 missed the $0.30 estimate by a wide margin. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TGTX — free to start on ORTEX.
Sign up for free →Open TGTX on ORTEX